YOUR SEARCH FOR Text 42 RESULTS
1 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… updated positive data from the Phase 1/2 trial evaluating axatilimab as a monotherapy in … doses being assessed in the pivotal AGAVE-201 trial. Additional trials of axatilimab are …
2 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… essential thrombocythemia (ET). Combination trials of ruxolitinib BID with zilurgisertib … patients. AGAVE-201, a global pivotal Phase 2 trial of axatilimab in patients with cGVHD is …
3 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… in vitiligo. We are also initiating pivotal trials across key development programs for both … was based on the successful randomized REACH3 trial comparing ruxolitinib with best available …
4 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… (MF): Final results from the Phase 2 trial in MF patients with a suboptimal response … was generally well-tolerated. A Phase 3 trial evaluating parsaclisib as an add-on to …
5 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… of multiple ongoing and planned combination trials with ruxolitinib. The Prescription Drug … suboptimal response to ruxolitinib. Combination trials of parsaclisib, INCB57643 (BET) and …
6 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results from ruxolitinib cream’s pivotal trials in vitiligo (TRuE-V), 52-week safety and … Ruxolitinib in GVHD: Data from the REACH3 trial of ruxolitinib versus best available …
7 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… clearance. The global pivotal Phase 2 AGAVE-201 trial of axatilimab monotherapy in patients with … the third line setting is ongoing. Additional trials of axatilimab are planned, including a …
8 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Disease (GVHD) – key highlights Combination trials of ruxolitinib twice daily (BID) with … (NSCLC): Phase 3 (POD1UM-304) MSI-high endometrial cancer: Phase 2 (POD1UM-101, POD1UM-204) …
9 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… Plans are underway to initiate two combination trials with axatilimab in cGVHD in mid-2024, including a Phase 2 combination trial with ruxolitinib and a Phase 3 combination …
10 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… AGAVE-201, a global pivotal Phase 2 trial of axatilimab in patients with chronic … future medical meeting. A Phase 1/2 combination trial of axatilimab in combination with …